Alzheimer's disease (AD) is a chronic neurodegenerative disorder caused by a combination
of events impairing normal neuronal function. Here we found a molecular bridge between …

Sex has a role in the incidence and outcome of neurological illnesses, also influencing the
response to treatments. Neuroinflammation is involved in the onset and progression of …

Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in Parkinson's
disease patients and represents a major limitation for the pharmacological management …

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by Aβ-driven
synaptic dysfunction in the early phases of pathogenesis. In the synaptic context, the actin …

Acetylcholinesterase inhibitors (AChEIs) are the only currently available drugs for treating
Alzheimer's Disease (AD). Some authors have suggested a function of AChEIs not only in the …

A correct clinical diagnosis in the early stage of Alzheimer Disease (AD) is mandatory given
the current available treatment with acetylcholine esterase inhibitors. Moreover, a early to …

Generation of amyloid peptide (Aβ) is at the beginning of a cascade that leads to Alzheimer’s
disease (AD). Amyloid precursor protein (APP), as well as β- and γ-secretases, is the …

Background Members of membrane-bound disintegrin metalloproteinases (ADAMs) were
shown to be capable of cleaving amyloid precursor protein (APP) at the α-cleavage site in …

N-Cadherin has an important role during dendrite arborization, axon guidance, and
synaptogenesis. In particular, at synaptic sites, N-cadherin is involved in the regulation of cell–cell …

The pathogenesis of Alzheimer's disease includes accumulation of toxic amyloid beta (Aβ)
peptides. A recently developed cell-permeable peptide, termed Tat-Pro, disrupts the complex …